| Rescinnamine | hsa00052 | Galactose metabolism | 1.12E-04 | 2 | P06280, O43451 | GLA, MGAM | More | |
| Rescinnamine | hsa00500 | Starch and sucrose metabolism | 3.16E-04 | 2 | O43451, P06737 | MGAM, PYGL | More | |
| Rescinnamine | hsa00730 | Thiamine metabolism | 2.53E-05 | 2 | P05186, P24666 | ALPL, ACP1 | More | |
| Rescinnamine | hsa00770 | Pantothenate and CoA biosynthesis | 1.27E-04 | 3 | O95498, O95497, Q9NRN7 | VNN2, VNN1, AASDHPPT | More | |
| Rescinnamine | hsa00983 | Drug metabolism - other enzymes | 2.44E-02 | 2 | P32320, P05164 | CDA, MPO | More | |
| Rescinnamine | hsa04060 | Cytokine-cytokine receptor interaction | 3.62E-02 | 4 | P27930, P14778, P25024, P25025 | IL1R2, IL1R1, CXCR1, CXCR2 | More | |
| Rescinnamine | hsa04071 | Sphingolipid signaling pathway | 1.94E-02 | 3 | Q9H228, P01375, Q9UQC2 | EDG8, TNF, GAB2 | More | |
| Rescinnamine | hsa04072 | Phospholipase D signaling pathway | 1.69E-02 | 3 | Q9UQC2, P25024, P25025 | GAB2, CXCR1, CXCR2 | More | |
| Rescinnamine | hsa04120 | Ubiquitin mediated proteolysis | 3.44E-02 | 4 | Q14145, Q13042, P62837, Q15751 | KEAP1, CDC16, UBE2D2, HERC1 | More | |
| Rescinnamine | hsa04210 | Apoptosis | 3.58E-02 | 4 | O76075, P01375, Q9NR28, Q16548 | DFFB, TNF, DIABLO, BCL2A1 | More | |
| Rescinnamine | hsa04217 | Necroptosis | 2.34E-02 | 4 | P01375, P48023, Q14765, Q99878 | TNF, FASLG, STAT4, H2AC14 | More | |
| Rescinnamine | hsa04340 | Hedgehog signaling pathway | 3.32E-02 | 2 | P49841, P22694 | GSK3B, PRKACB | More | |
| Rescinnamine | hsa04657 | IL-17 signaling pathway | 3.31E-02 | 3 | P49841, P14780, P01375 | GSK3B, MMP9, TNF | More | |
| Rescinnamine | hsa04722 | Neurotrophin signaling pathway | 3.27E-02 | 3 | P49841, O43524, P48023 | GSK3B, FOXO3, FASLG | More | |
| Rescinnamine | hsa04910 | Insulin signaling pathway | 2.35E-02 | 3 | P22694, P06737, P49841 | PRKACB, PYGL, GSK3B | More | |
| Rescinnamine | hsa04919 | Thyroid hormone signaling pathway | 7.11E-03 | 4 | P49841, P22694, O60244, Q9NVC6 | GSK3B, PRKACB, MED14, MED17 | More | |
| Rescinnamine | hsa04931 | Insulin resistance | 1.94E-02 | 3 | P01375, P49841, P06737 | TNF, GSK3B, PYGL | More | |
| Rescinnamine | hsa04932 | Non-alcoholic fatty liver disease | 2.74E-02 | 3 | P01375, P49841, P48023 | TNF, GSK3B, FASLG | More | |
| Rescinnamine | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
| Rescinnamine | hsa04976 | Bile secretion | 2.44E-02 | 2 | P22694, P08183 | PRKACB, ABCB1 | More | |
| Rescinnamine | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 3.73E-02 | 2 | P25024, P25025 | CXCR1, CXCR2 | More | |
| Rescinnamine | hsa05143 | African trypanosomiasis | 2.72E-02 | 2 | P01375, P48023 | TNF, FASLG | More | |
| Rescinnamine | hsa05160 | Hepatitis C | 1.27E-02 | 4 | P60033, P49841, P01375, P48023 | CD81, GSK3B, TNF, FASLG | More | |
| Rescinnamine | hsa05330 | Allograft rejection | 2.72E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
| Rescinnamine | hsa05332 | Graft-versus-host disease | 3.70E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
